These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 25712992)

  • 21. Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study.
    Hilliard P; Zourikian N; Blanchette V; Chan A; Elliott B; Israels SJ; Nilson J; Poon MC; Laferriere N; Van Neste C; Jarock C; Wu J; McLimont M; Feldman B
    J Thromb Haemost; 2013 Mar; 11(3):460-6. PubMed ID: 23301594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Personalized prophylaxis in people with hemophilia A: challenges and achievements.
    Ar MC; Baslar Z; Soysal T
    Expert Rev Hematol; 2016 Dec; 9(12):1203-1208. PubMed ID: 27809624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathophysiology, diagnosis and prevention of arthropathy in patients with haemophilia.
    Dunn AL
    Haemophilia; 2011 Jul; 17(4):571-8. PubMed ID: 21342365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment Individualization Using Pharmacokinetic Studies and Joint Ultrasound Imaging in Pediatric Patients With Hemophilia.
    Adramerina A; Teli A; Symeonidis S; Gelsis I; Gourtsa V; Economou M
    J Pediatr Hematol Oncol; 2022 Jul; 44(5):237-242. PubMed ID: 34486567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study.
    Schobess R; Kurnik K; Friedrichs F; Halimeh S; Krümpel A; Bidlingmaier C; Nowak-Göttl U
    Thromb Haemost; 2008 Jan; 99(1):71-6. PubMed ID: 18217137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Forum on: the role of recombinant factor VIII in children with severe haemophilia A.
    Franchini M; Coppola A; Molinari AC; Santoro C; Schinco P; Speciale V; Tagliaferri A
    Haemophilia; 2009 Mar; 15(2):578-86. PubMed ID: 19187188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploration of the pathogenesis of haemophilic joint arthropathy: understanding implications for optimal clinical management.
    Acharya SS
    Br J Haematol; 2012 Jan; 156(1):13-23. PubMed ID: 22050780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. When should prophylactic treatment in patients with haemophilia A and B start?--The German experience.
    Kreuz W; Escuriola-Ettingshausen C; Funk M; Schmidt H; Kornhuber B
    Haemophilia; 1998 Jul; 4(4):413-7. PubMed ID: 9873763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention and treatment of musculoskeletal disease in the haemophilia population: role of prophylaxis and synovectomy.
    Van den Berg HM; Dunn A; Fischer K; Blanchette VS
    Haemophilia; 2006 Jul; 12 Suppl 3():159-68. PubMed ID: 16684012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors.
    Chai-Adisaksopha C; Nevitt SJ; Simpson ML; Janbain M; Konkle BA
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011441. PubMed ID: 28944952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secondary prophylaxis therapy: what are the benefits, limitations and unknowns?
    Valentino LA
    Haemophilia; 2004 Mar; 10(2):147-57. PubMed ID: 14962203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of haemophilic arthropathy.
    Bossard D; Carrillon Y; Stieltjes N; Larbre JP; Laurian Y; Molina V; Dirat G
    Haemophilia; 2008 Jul; 14 Suppl 4():11-9. PubMed ID: 18494688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathogenesis, early diagnosis, and prophylaxis for chronic hemophilic synovitis.
    Rodríguez-Merchán EC
    Clin Orthop Relat Res; 1997 Oct; (343):6-11. PubMed ID: 9345198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A history of prophylaxis in haemophilia.
    Moreno MM; Cuesta-Barriuso R
    Blood Coagul Fibrinolysis; 2019 Sep; 30(1S Suppl 1):S1-S3. PubMed ID: 31517707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A cohort study of the usefulness of primary prophylaxis in patients with severe haemophilia A.
    Nagae C; Yamashita A; Ashikaga T; Mori M; Akita M; Kitsukawa K; Yamazaki S; Yoshikawa K; Yamamoto H; Taki M
    Int J Hematol; 2016 Aug; 104(2):208-15. PubMed ID: 27125646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
    Young G; Mahlangu J; Kulkarni R; Nolan B; Liesner R; Pasi J; Barnes C; Neelakantan S; Gambino G; Cristiano LM; Pierce GF; Allen G
    J Thromb Haemost; 2015 Jun; 13(6):967-77. PubMed ID: 25912075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of prophylactic treatment regimens in children with severe haemophilia: a comparison of different strategies.
    van den Berg HM; Fischer K; van der Bom JG; Roosendaal G; Mauser-Bunschoten EP
    Haemophilia; 2002 Mar; 8 Suppl 2():43-6. PubMed ID: 11966853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens.
    Berntorp E
    Haemophilia; 2009 Nov; 15(6):1219-27. PubMed ID: 19659939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Importance of pharmacokinetics in the management of hemophilia.
    Barnes C
    Pediatr Blood Cancer; 2013; 60 Suppl 1():S27-9. PubMed ID: 23109436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prophylaxis in people with haemophilia.
    Coppola A; Franchini M; Tagliaferri A
    Thromb Haemost; 2009 Apr; 101(4):674-81. PubMed ID: 19350110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.